keyword
MENU ▼
Read by QxMD icon Read
search

Sacubitril valsartan

keyword
https://www.readbyqxmd.com/read/29327807/uric-acid-is-important-but-there-is-something-that-matters-even-more-to-deliver-sacubitril-valsartan-to-eligible-heart-failure-patients
#1
EDITORIAL
Maria Rosa Costanzo
No abstract text is available yet for this article.
January 12, 2018: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29325796/lcz696-sacubitril-valsartan-an-angiotensin-receptor-neprilysin-inhibitor-attenuates-cardiac-hypertrophy-fibrosis-and-vasculopathy-in-a-rat-model-of-chronic-kidney-disease
#2
Yasunori Suematsu, Wanghui Jing, Ane Nunes, Moti L Kashyap, Mahyar Khazaeli, Nosratola D Vaziri, Hamid Moradi
BACKGROUND: Chronic kidney disease (CKD) is associated with cardiac hypertrophy, fibrosis and increased risk of cardiovascular mortality. LCZ696 (Sacubitril/valsartan) is a promising agent which has shown significant potential in treatment of heart failure. We hypothesized that LCZ696 is more effective than valsartan alone in treatment of cardiovascular abnormalities associated with experimental CKD. METHODS AND RESULTS: Male Sprague Dawley rats underwent 5/6 nephrectomy and were subsequently randomized to no treatment (CKD), 30 mg/kg valsartan (VAL), or 60 mg/kg LCZ696 (LCZ)...
January 8, 2018: Journal of Cardiac Failure
https://www.readbyqxmd.com/read/29324464/sacubitril-valsartan-associated-small-bowel-ileus
#3
Lilianna Hanefeld-Fox, Lissette Jimenez, Rebecca Heflin, Luis Quiel
No abstract text is available yet for this article.
January 8, 2018: American Journal of Therapeutics
https://www.readbyqxmd.com/read/29318651/effect-of-the-angiotensin-receptor-neprilysin-inhibitor-sacubitril-valsartan-on-pharmacokinetics-and-pharmacodynamics-of-a-single-dose-of-furosemide
#4
Surya Ayalasomayajula, Uwe Schuehly, Parasar Pal, Fabian Chen, Wei Zhou, Gangadhar Sunkara, Thomas H Langenickel
AIMS: Sacubitril/valsartan is indicated for the treatment of heart failure and reduced ejection fraction (HFrEF). Furosemide, a loop diuretic commonly used for the treatment of HFrEF, may be co-administrated with sacubitril/valsartan in clinical practice. The effect of sacubitril/valsartan on pharmacokinetics and pharmacodynamics of furosemide was evaluated in this open label, two- period, single-sequence study in healthy subjects (N=28). METHODS: All subjects received 40 mg oral single dose furosemide during period 1 followed by washout of 2 days...
January 9, 2018: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29286056/sacubitril-and-valsartan-fixed-combination-to-reduce-heart-failure-events-in-post-acute-myocardial-infarction-patients
#5
M Zaid Iskandar, C C Lang
Heart failure is a term used to define a constellation of symptoms and signs that are commonly attributed to the inability of the heart to produce a cardiac output that meets the demands of the body. It remains a deadly disease, affecting between 1-2% of the population, and is more common in the elderly, with around 6-10% of patients over 65 suffering from the condition. Sacubitril/valsartan (LCZ-696) is a combined neprilysin inhibitor and angiotensin AT1 receptor blocker approved in recent years for the treatment of chronic heart failure with reduced ejection fraction...
October 2017: Drugs of Today
https://www.readbyqxmd.com/read/29262406/sacubitril-valsartan-in-clinical-practice-the-italian-experience
#6
Roberto Valle, Nadia Aspromonte
No abstract text is available yet for this article.
2017: Cardiology
https://www.readbyqxmd.com/read/29262405/management-of-a-multicomorbid-patient-with-heart-failure
#7
Gianluigi Magri, Crescenzio Bentivenga, Eugenio Roberto Cosentino, Daniela Degli Esposti, Claudio Borghi, Ada Dormi
The optimal use of sacubitril/valsartan in clinical practice needs further investigation, in particular for patients with multiple comorbidities, as such patients are usually poorly represented in clinical trials. To this end, well-documented case reports may add further evidence to the bulk of "field practice" experience on sacubitril/valsartan. We report here the case of a patient with heart failure with reduced ejection refraction with multiple comorbidities treated with sacubitril/valsartan. Overall, sacubitril/valsartan led to a prompt (within a few months) improvement in LVEF (+15%, from 38 to 53%), without any noticeable adverse events...
2017: Cardiology
https://www.readbyqxmd.com/read/29262403/sacubitril-valsartan-in-an-elderly-patient-with-heart-failure-a-case-report
#8
Matteo Cameli, Maria Concetta Pastore, Antonio Pagliaro, Cristina Di Tommaso, Rosanna Reccia, Valeria Curci, Giulia Elena Mandoli, Sergio Mondillo
Sacubitril/valsartan has recently been approved for the treatment of heart failure with reduced ejection fraction. Given its recent introduction in the armamentarium for the treatment of heart failure (HF), "field-practice" evidence is required to deepen the clinical management of sacubitril/valsartan therapy. We report a relevant case of an elderly patient who achieved major clinical benefits after only 3 months of sacubitril/valsartan therapy. Importantly, in our assessment, we employed speckle tracking echocardiography (STE), a recent echocardiography technique that is non-Doppler and not angle dependent, which analyzes deformations of heart chambers from standard images and allows a fast, reliable, and reproducible assessment of heart function...
2017: Cardiology
https://www.readbyqxmd.com/read/29262402/sacubitril-valsartan-in-field-practice-patients-with-advanced-heart-failure-a-monocentric-italian-experience
#9
Antonella Vincenzi, Francesca Cesana, Antonio Cirò, Laura Garatti, Felice Achilli
Patients with advanced heart failure (HF) experience a continuous decline in quality of life and have a very poor prognosis. Moreover, due to numerous comorbidities present in these patients, transplantation and left ventricular assist devices are usually impracticable in clinical practice. In this challenging setting, administration of inotropic agents may be the only possible therapy; however, this treatment requires frequent hospitalizations. Our hypothesis is that sacubitril/valsartan, given its marked efficacy and manageability, can be safely used in clinical practice in this setting, potentially reducing hospitalizations and the need for inotropic support...
2017: Cardiology
https://www.readbyqxmd.com/read/29262400/sacubitril-valsartan-effect-on-walking-test-and-physical-capability
#10
Luca Sgorbini, Antonella Rossetti, Alfonso Galati
The 6-min walk test (6MWT) is a simple and inexpensive exercise test to evaluate physical functional capacity that is widely used in heart failure (HF) patients. With the 6MWT, a distance <350 m is associated with increased mortality in patients with HF, and change in walking distance >50 m is considered clinically relevant. To our knowledge, information on improvement in physical functional capacity with sacubitril/valsartan, as assessed by the 6MWT, is still scant. In our daily practice, we apply this test to all patients whenever possible; therefore, we report here the findings observed in a small series of 5 patients with HF with reduced ejection fraction after a 1-month treatment with sacubitril/valsartan at full dose...
2017: Cardiology
https://www.readbyqxmd.com/read/29262399/sacubitril-valsartan-in-clinical-practice-a-report-of-2-cases
#11
Eugenio Cosentino
Following the results of the PARADIGM-HF trial, the European Society of Cardiology (ESC) guidelines recommend sacubitril/valsartan to replace ACE inhibitors in ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite optimal therapy and who fit trial criteria. However, the optimal use of sacubitril/valsartan in clinical practice needs further investigation. We report here the cases of 2 patients with HFrEH successfully treated with sacubitril/valsartan in our daily practice...
2017: Cardiology
https://www.readbyqxmd.com/read/29262397/pharmacological-management-of-a-heart-failure-patient-with-severe-obesity
#12
Gerardo Riccio
Obesity is one of the commonest comorbidities in patients with heart failure, and it is associated with increased mortality risk. However, obese patients are often underrepresented in clinical trials and therefore evidence on their management remains scant. In order to expand knowledge on the management of these patients, anecdotal reports may be considered. In the present case report, we discuss the successful management of an obese patient who received sacubitril/valsartan therapy. This treatment was initiated after a 12-month period of losartan therapy, which did not provide any benefit in terms of heart function...
2017: Cardiology
https://www.readbyqxmd.com/read/29249422/sacubitril-valsartan-and-short-term-changes-in-the-6-minute-walk-test-a-pilot-study
#13
Paola Beltrán, Patricia Palau, Eloy Domínguez, Mercedes Faraudo, Eduardo Núñez, Olga Guri, Anna Mollar, Juan Sanchis, Antoni Bayés-Genís, Julio Núñez
BACKGROUND: Impaired exercise capacity is the most disabling symptom in patients with heart failure with reduced ejection fraction (HFrEF). Despite sacubitril/valsartan showing reduced long-term morbidity and mortality over enalapril in HFrEF, its effects on short-term functional capacity remain uncertain. We sought to evaluate the effects of sacubitril/valsartan on a 30-day six-minute walk test in eligible patients with HFrEF. METHODS AND RESULTS: From November 1, 2016 to February 1, 2017, a total of 58 stable symptomatic patients with HFrEF were eligible for sacubitril/valsartan and underwent 6-MWT before and 30days after initiation of sacubitril/valsartan therapy...
February 1, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29241885/cost-effectiveness-of-the-angiotensin-receptor-neprilysin-inhibitor-sacubitril-valsartan-for-patients-with-chronic-heart-failure-and-reduced-ejection-fraction-in-the-netherlands-a-country-adaptation-analysis-under-the-former-and-current-dutch-pharmacoeconomic
#14
COMPARATIVE STUDY
Isaac Corro Ramos, Matthijs M Versteegh, Rudolf A de Boer, Jolanda M A Koenders, Gerard C M Linssen, Joan G Meeder, Maureen P M H Rutten-van Mölken
OBJECTIVES: To describe the adaptation of a global health economic model to determine whether treatment with the angiotensin receptor neprilysin inhibitor LCZ696 is cost effective compared with the angiotensin-converting enzyme inhibitor enalapril in adult patients with chronic heart failure with reduced left ventricular ejection fraction in the Netherlands; and to explore the effect of performing the cost-effectiveness analyses according to the new pharmacoeconomic Dutch guidelines (updated during the submission process of LCZ696), which require a value-of-information analysis and the inclusion of indirect medical costs of life-years gained...
December 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29239515/rationale-and-design-of-transition-a-randomized-trial-of-pre-discharge-vs-post-discharge-initiation-of-sacubitril-valsartan
#15
Domingo Pascual-Figal, Rolf Wachter, Michele Senni, Jan Belohlavek, Adele Noè, David Carr, Dmytro Butylin
AIMS: The prognosis after hospitalization for acute decompensated heart failure (ADHF) remains poor, especially <30 days post-discharge. Evidence-based medications with prognostic impact administered at discharge improve survival and hospital readmission, but robust studies comparing pre-discharge with post-discharge initiation are rare. The PARADIGM-HF trial established sacubitril/valsartan as a new evidence-based therapy in patients with heart failure (HF) and reduced left ventricular ejection fraction (<40%) (rEF)...
December 14, 2017: ESC Heart Failure
https://www.readbyqxmd.com/read/29237097/sacubitril-valsartan-instead-of-renin-angiotensin-system-inhibition-alone-a-step-forward-in-resistant-hypertension
#16
Konstantinos Stavropoulos, Konstantinos P Imprialos, Michael Doumas
No abstract text is available yet for this article.
December 13, 2017: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29232274/from-theory-to-practice-the-diuretic-potential-of-sacubitril-valsartan-a-tale-of-2-patients
#17
Sabrina M Hormann, Lindsay E Davis, Elizabeth K Pogge
BACKGROUND: Heart failure prevalence continues to rise in the United States causing significant morbidity and mortality and costing billions in healthcare expenditures. Consensus guidelines updated in 2016 recommend an angiotensin receptor-neprilysin inhibitor (ARNi) as a therapeutic option in lieu of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker for the management of stage C heart failure with reduced ejection fraction (HFrEF). For chronic HFrEF patients with New York Heart Association class II or III symptoms tolerating an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, a change in therapy to an ARNi is recommended to further reduce morbidity and mortality...
December 11, 2017: Journal of Cardiovascular Nursing
https://www.readbyqxmd.com/read/29193563/sacubitril-valsartan-reduces-serum-uric-acid-concentration-an-independent-predictor-of-adverse-outcomes-in-paradigm-hf
#18
Ulrik M Mogensen, Lars Køber, Pardeep S Jhund, Akshay S Desai, Michele Senni, Søren L Kristensen, Andrej Dukát, Chen-Huan Chen, Felix Ramires, Martin P Lefkowitz, Margaret F Prescott, Victor C Shi, Jean L Rouleau, Scott D Solomon, Karl Swedberg, Milton Packer, John J V McMurray
AIMS: Elevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders. We examined the association between SUA and outcomes as well as the effect of sacubitril/valsartan on SUA in patients with heart failure with reduced ejection fraction (HFrEF) in PARADIGM-HF. METHODS AND RESULTS: The association between SUA and the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization, its components, and all-cause mortality was examined using Cox regression analyses among 8213 patients using quintiles (Q1-Q5) of SUA adjusted for baseline prognostic variables including estimated glomerular filtration rate (eGFR), diuretic dose, and log N-terminal pro-brain natriuretic peptide...
November 30, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29192956/initial-clinical-experience-with-the-first-drug-sacubitril-valsartan-in-a-new-class-arnis-in-patients-with-heart-failure-with-reduced-left-ventricular-ejection-fraction-in-poland
#19
Marta Kałużna-Oleksy, Jolanta Kolasa, Jacek Migaj, Agnieszka Pawlak, Małgorzata Lelonek, Jadwiga Nessler, Ewa Straburzyńska-Migaj
Sacubitril/valsartan is the first drug from a new class of angiotensin receptor neprilisin inhibitors (ARNIs) recommended in the new European Society of Cardiology's guidelines instead of ACEIs, or ARBs (angiotensin receptor antagonists) used if ACEIs are not tolerated, for further reduction in the risk of hospitalisation or death in outpatients with HFrEF if symptoms continue despite optimal treatment with ACEIs/ARBs, betablockers and MRAs (mineralocorticoid antagonists). The aim of this paper is to present the initial experience with regard to the effectiveness, tolerance and safety of sacubitril/valsartan in the outpatient cardiology practice in Poland...
December 1, 2017: Kardiologia Polska
https://www.readbyqxmd.com/read/29185253/cost-effectiveness-of-sacubitril-valsartan-in-chronic-heart-failure-patients-with-reduced-ejection-fraction
#20
Zanfina Ademi, Alena M Pfeil, Elizabeth Hancock, David Trueman, Rola Haroun Haroun, Celine Deschaseaux, Matthias Schwenkglenks
AIMS: We aimed to assess the cost effectiveness of sacubitril/valsartan compared to angiotensin-converting enzyme inhibitors (ACEIs) for the treatment of individuals with chronic heart failure and reduced-ejection fraction (HFrEF) from the perspective of the Swiss health care system. METHODS: The cost-effectiveness analysis was implemented as a lifelong regression-based cohort model. We compared sacubitril/valsartan with enalapril in chronic heart failure patients with HFrEF and New York-Heart Association Functional Classification II-IV symptoms...
November 29, 2017: Swiss Medical Weekly
keyword
keyword
113633
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"